Conditional relative survival among patients with chronic lymphocytic leukaemia:A population-based study in the Netherlands
Studies on conditional relative survival (CRS) in chronic lymphocytic leukaemia (CLL) have hitherto been lacking in the literature. We predicted up-to-date estimates of 5-year RS at diagnosis and for each additional year survived (i.e., CRS) up to 15 years post-diagnosis among CLL patients diagnosed during 2007-2020. We showed that 5-year CRS continues to decline gradually with each additional year survived in a contemporary era with access to novel-based agents, irrespective of age. This finding indicates that CLL patients continue to experience substantial excess mortality compared to an age... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Reihe/Periodikum: | van der Straten , L , Levin , M-D , Visser , O , Posthuma , E F M , Doorduijn , J K , Kater , A P & Dinmohamed , A G 2022 , ' Conditional relative survival among patients with chronic lymphocytic leukaemia : A population-based study in the Netherlands ' , eJHaem , vol. 3 , no. 1 , pp. 180-183 . https://doi.org/10.1002/jha2.368 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27617697 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://pure.eur.nl/en/publications/81a6139c-157c-4e86-8d58-7301955801bd |
Studies on conditional relative survival (CRS) in chronic lymphocytic leukaemia (CLL) have hitherto been lacking in the literature. We predicted up-to-date estimates of 5-year RS at diagnosis and for each additional year survived (i.e., CRS) up to 15 years post-diagnosis among CLL patients diagnosed during 2007-2020. We showed that 5-year CRS continues to decline gradually with each additional year survived in a contemporary era with access to novel-based agents, irrespective of age. This finding indicates that CLL patients continue to experience substantial excess mortality compared to an age- and sex-matched group from the general population.